TARA News and Press, ArTara Therapeutics Inc. From 06/21/22

Protara Therapeutics (TARA) has announced that its CFO, Blaine Davis, will be leaving to pursue other opportunities and his last day will be July 15, 2022. Mr. Davis’ departure is not related to Protara’s operations, financial reporting or controls. As of March 31, 2022, th...

NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that Blaine Davis, Chief Financial Officer (CFO), has informed the Company t...

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCE...

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright Global Investment Confer...

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the results of a retrospective analysis of OK-432, the originator compound fo...

ArTara Therapeutics press release (NASDAQ:TARA): Q1 GAAP EPS of -$0.96 misses by $0.06. As of March 31, 2022, cash, cash equivalents and restricted cash were $118.5 million. The Company expects its current cash and cash equivalents will be sufficient to fund its planned operations into mid-20...

- Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash Equivalents and Investments Position of $119M as of March 31, 2022 Expected to Fund Operations into Mid-2024 - NEW YORK, May 05, ...

Protara Therapeutics (NASDAQ:TARA) said it dosed the first patient in a phase 1 trial of its cell therapy TARA-002 to treat non-muscle invasive bladder cancer (NMIBC). The primary objective of the early-stage trial, dubbed ADVANCED-1, is to evaluate the safety, tolerability and signs of ...

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has dosed the first patient in ADVANCED-1, its Phase 1 cl...

ArTara Therapeutics press release (NASDAQ:TARA): Q4 GAAP EPS of -$0.91 beats by $0.03. As of December 31, 2021, cash, cash equivalents and marketable debt securities totaled $130.7 million. For further details see: ArTara Therapeutics GAAP EPS of -$0.91 beats by $0.03